GMVD - NASDAQ IPO, page-1221

page 3

We have adopted a three-phase approach for the deployment of our IDTF platform which includes evaluation, implementation and treatment phases. Ten university hospitals in the United States are now in the treatment phase, another seven hospitals are near completion of the implementation phase and we are witnessing an increase in patient enrolment that we expect to continue. We receive approximately between $175 to $750 in reimbursement per patient monitored depending on specific modality. We have been approved and CPT-coded with more than 150 healthcare insurance providers to be reimbursed by our services.